These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 8620483

  • 1. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG.
    Cancer Res; 1996 Apr 15; 56(8):1727-30. PubMed ID: 8620483
    [Abstract] [Full Text] [Related]

  • 2. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 3. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ.
    Prostate; 2005 Jan 01; 62(1):69-82. PubMed ID: 15389805
    [Abstract] [Full Text] [Related]

  • 4. Prolonged inhibition by X-rays of DNA synthesis in cells obtained by transformation of primary rat embryo fibroblasts with oncogenes H-ras and v-myc.
    Wang Y, Iliakis G.
    Cancer Res; 1992 Feb 01; 52(3):508-14. PubMed ID: 1732037
    [Abstract] [Full Text] [Related]

  • 5. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 15; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 8. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.
    J Med Chem; 1996 Jan 05; 39(1):224-36. PubMed ID: 8568812
    [Abstract] [Full Text] [Related]

  • 9. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 05; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 10. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
    Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G.
    Radiat Res; 1999 Oct 05; 152(4):404-11. PubMed ID: 10477917
    [Abstract] [Full Text] [Related]

  • 11. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.
    Leukemia; 2003 Feb 05; 17(2):451-7. PubMed ID: 12592346
    [Abstract] [Full Text] [Related]

  • 12. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE.
    Cancer Res; 1996 Jun 01; 56(11):2626-32. PubMed ID: 8653708
    [Abstract] [Full Text] [Related]

  • 13. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W, Lebowitz PF, Prendergast GC.
    Cancer Res; 1999 May 01; 59(9):2059-63. PubMed ID: 10232587
    [Abstract] [Full Text] [Related]

  • 14. Synergistic effect of the v-myc oncogene with H-ras on radioresistance.
    McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, Muschel RJ.
    Cancer Res; 1990 Jan 01; 50(1):97-102. PubMed ID: 2403420
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
    Kim J, Seong J, Kim SH.
    Ann N Y Acad Sci; 2004 Dec 01; 1030():95-102. PubMed ID: 15659785
    [Abstract] [Full Text] [Related]

  • 16. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B, Prendergast GC, Fenton RG.
    Cancer Res; 2002 Jan 15; 62(2):450-8. PubMed ID: 11809695
    [Abstract] [Full Text] [Related]

  • 17. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R.
    Oncogene; 1995 May 04; 10(9):1763-79. PubMed ID: 7753553
    [Abstract] [Full Text] [Related]

  • 18. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F, Park M, Goltzman D, Rabbani SA.
    Cancer Res; 1997 Oct 15; 57(20):4517-22. PubMed ID: 9377563
    [Abstract] [Full Text] [Related]

  • 19. Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade.
    Oldham SM, Cox AD, Reynolds ER, Sizemore NS, Coffey RJ, Der CJ.
    Oncogene; 1998 May 15; 16(20):2565-73. PubMed ID: 9632133
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM.
    Oncogene; 2000 Nov 16; 19(48):5525-33. PubMed ID: 11114730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.